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Synthetic peptides incorporating protective B- and T-cell epitopes are candidates for new safer foot-and-mouth disease (FMD)
vaccines. We have reported that dendrimeric peptides including four copies of a B-cell epitope (VP1 136 to 154) linked to a T-cell
epitope (3A 21 to 35) of FMD virus (FMDV) elicit potent B- and T-cell specific responses and confer protection to viral challenge,
while juxtaposition of these epitopes in a linear peptide induces less efficient responses. To assess the relevance of B-cell epitope
multivalency, dendrimers bearing two (B
2
T) or four (B
4
T) copies of the B-cell epitope from typeO FMDV (awidespread circulating
serotype) were tested in CD1 mice and showed that multivalency is advantageous over simple B-T-epitope juxtaposition, resulting
in efficient induction of neutralizing antibodies and optimal release of IFN𝛾. Interestingly, the bivalent B
2
T construction elicited
similar or even better B- and T-cell specific responses than tetravalent B
4
T. In addition, the presence of the T-cell epitope and its
orientation were shown to be critical for the immunogenicity of the linear juxtaposed monovalent peptides analyzed in parallel.
Taken together, our results provide useful insights for a more accurate design of FMD subunit vaccines.
1. Introduction
Foot-and-mouth disease (FMD) is a highly infectious disease
of cloven-hoofed animals, admittedly the most important
livestock disease in terms of economic impact [1, 2]. In many
areas of the world (Africa, Asia, and to some extent South
America)where it remains endemic, FMDseverely handicaps
access to international meat markets [3]. FMD control in
endemic regions is implemented mainly by using chemically
inactivated whole-virus vaccines whose production (large-
scale growth of virulent FMD virus (FMDV), virus inactiva-
tion, antigen concentration, and purification) has remained
largely the same for decades [4, 5]. This practice poses
serious biosafety concerns, as the risk of virus release during
vaccine production is well documented [4, 6]. Additional
shortcomings of current FMD vaccines include the need for
a cold chain to preserve virus stability and the difficulty
of serological distinction between infected and vaccinated
animals [4]. These concerns, along with the severe trade
restrictions applied in any vaccination campaign, have led
FMDV-free countries to adopt nonvaccination policies in
the event of an FMD outbreak. Such policies have involved
massive slaughtering of infected or suspected (contact) herds,
as well as strict limitations on farm animal movements, all of
which have raised significant controversies [7, 8].
In this context, peptide-based approaches appear to be
an attractive strategy for FMD vaccine development. Peptide
vaccines offer several advantages over other types of vaccines
such as (i) lack of infectious agent, which ensures absolute
safety, (ii) accurate molecular delineation of the immunogen,
which allows to exclude detrimental sequences present in
full-length antigens or other pathogen-relatedmolecules, and
permits easy differentiation of infected from vaccinated ani-
mals (referred as DIVA vaccines), (iii) easy access and scale
up by peptide synthesis methods, and (iv) uncomplicated
transport and storage [9, 10]. However, despite their promises
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candidates for next-generation vaccines and peptides are
typically poorly immunogenic.
In the case of FMD, the main antigenic sites recognized
by B lymphocytes have been identified at defined structural
motifs exposed on the surface of the FMDV capsid, whose
amino acid sequences accumulate variations among different
serotypes [11, 12]. A continuous, immunodominant B-cell
site located in the GH loop, around positions 140 to 160 of
capsid protein VP1, has been widely used as an immunogenic
peptide [13]. However, the protection against FMD conferred
to natural hosts by linear peptides spanning the GH loop
of VP1 is limited [13, 14]. Although it is generally accepted
that protective immunity to FMDV is mostly due to neu-
tralizing antibodies, a T-cell response is also necessary for
effective immunity [15]. We have reported that inclusion of
a specific T-cell epitope located in residues 21 to 35 of FMDV
NS protein 3A [16], juxtaposed in a linear fashion to the
above-mentioned B-cell epitope, affords significant reduction
in virus excretion and clinical scores after challenge [17].
This monomeric peptide B-T, however, did not afford full
protection in challenged pigs.
In order to enhance the effectiveness of presentation of
the above B- and T-cell epitopes to the immune system,
a multimerization approach consisting of a dendrimeric
peptide bearing four copies of the B-cell epitope and one
of the Th epitope was explored. The branched construct,
generically known as B
4
T, elicited high titers of FMDV-
neutralizing and IgA antibodies in both pig and outbred
mice (CD1 strain) activated T-cells and induced IFN𝛾 release.
The dendrimer performed as an effective peptide vaccine
conferring solid protection in swine against type C FMDV
challenge [18].
With a view to extending these proof-of-concept
results to epidemiologically relevant FMDV serotypes, we
have designed and produced new B
4
T constructs harbor-
ing sequences from type O FMDV (currently the most
widespread serotype) [3, 19] as B-cell epitopes. To assess the
relevance of B-cell epitope multivalency, constructs bearing
two (B
2
T) or four (B
4
T) copies of the B-cell epitope were
tested in CD1 mice, showing that multivalency is advant-
ageous over simple B-T-epitope juxtaposition but also that
bivalent B
2
T constructions elicit similar or even better
humoral and cellular specific responses than tetravalent ones
[20]. Herein we show that epitope density is essential for
inducing an efficient humoral immune response, including
neutralizing antibodies, but also for optimal release of
IFN𝛾, a relevant antiviral cytokine. In addition, we evaluate
the orientation of T-relative to B-cell epitopes in juxta-
posed monovalent constructs in terms of efficient T-B
cell cooperation and induction of cellular response. Taken
together, our results provide useful insights for a more accu-
rate design of subunit vaccines.
2. Materials and Methods
2.1. Peptides. Peptides reproducing the B [VP1(136–150)] and
T [3A(21–35)] epitopes of type O FMDV (O-UKG 11/01) in
different arrangements are shown in Table 1. Linear B, T, BT
and TB peptides were made by Fmoc solid phase synthesis as
previously described [17]. Bi- and tetravalent constructs B
2
T
and B
4
Tweremade by thioether ligation protocols as detailed
in Monso et al. [20] and Cubillos et al. [18], respectively. All
six peptides were purified by reverse phase HPLC to >95%
purity and satisfactorily characterized by MALDI-TOF mass
spectrometry.
2.2. Virus. A virus stock derived from serotype O-UKG 11/01
(supplied by The Pirbright Institute, UK) by two amplifi-
cations in IBRS-2 cells, which maintained the consensus
sequences at the capsid protein region, was used in this study.
2.3. Mice and Immunization. The immune response induced
by the various peptide constructions on Table 1 was assessed
in outbred Swiss mice (Swiss ICR-CD1, Harlan Laboratories).
5- to 6-week-old female mice in groups of 6 to 9 were main-
tained under standard housing conditions in the CBMSO
Animal Care unit. Mice were immunized subcutaneously
at days 0 and 18 with 100 𝜇g of each peptide emulsified in
Montanide ISA 50V2 (Seppic, France) and sacrificed at day
39. Two groups of 4 mice each were immunized as controls
with either adjuvant or PBS. Blood samples were collected by
tail bleeding before priming (day 0) and at days 14, 20, and
39 (sacrifice). All experimental procedures were conducted
in accordancewith protocols approved by theCBMSO ethical
committee.
2.4. Virus Neutralization Test (VNT). Virus neutralization
activity was determined in sera by a standard microneutral-
ization test performed in 96-well plates by incubating serial
twofold dilutions of each serum sample with 100 50% tissue
culture infective dose (TCID50) of FMDVO-UK/01, for 1 h at
37∘C.The remaining viral activity was determined in 96-well
plates containing freshmonolayers of BHK-21 cells. Endpoint
titers were calculated as the reciprocal of the final serum
dilution that neutralized 100 TCID50 of FMDV (O-UK/01)
in 50% of the wells [22].
2.5. Detection of Specific Anti-FMDV Antibodies By ELISA.
Total antibodies against FMDV were examined by ELISA
in serum samples collected at day 39. Briefly, Maxisorp 96-
well plates (Nunc) were coatedwith sucrose gradient-purified
140’s FMDV O UKG 11/2001 particles in PBS overnight at
4∘C (0.1𝜇g/well). Then, wells were washed with PBS and
blocked with 5% skimmed milk in PBS for 2 h at 37∘C.
Duplicate threefold dilution series of each serum sample were
prepared, starting at 1/100 and made up at 50 𝜇L. Preim-
mune sera from peptide-immunized mice and sera from
nonimmunized animals were used as negative controls. Spe-
cific antibodies were detected with horse radish peroxidase-
(HRP-) conjugated goat anti-mouse IgG (Zymed, Invitro-
gen), diluted 1/3000. Colour development was obtained after
addition of 100 𝜇L/well of the soluble substrate 3,3󸀠,5,5󸀠-
tetramethylbenzidine (TMB, Sigma) and stopped by an equal
volume of 1M H
2
SO
4
. Plates were read in a Fluostar Omega
microplate reader at 450 nm. In this assay, it was found that
the point on the titration curve corresponding to an A
450
of
1.0 invariably fell on the linear part of the curve. Antibody
titers were therefore expressed as the reciprocal of the last
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Table 1
Peptide
name FMDV protein (residues) Structure
∗
B VP1 (136–154) PVTNVRGDLQVLAQKAART
T 3A (21–35) AAIEFFEGMVHDSIK
BT VP1 (136–154)-3A (21–35) PVTNVRGDLQVLAQKAARTAAIEFFEGMVHDSIK
TB 3A (21–35)-VP1 (136–154) AAIEFFEGMVHDSIKPVTNVRGDLQVLAQKAART
B2T [VP1 (136–154)]2-3A (21–35)
Ac-PVTNVRGDLQVLAQKAARTC
Ac-PVTNVRGDLQVLAQKAARTC
O
O
KK–KAAIEFFEGMVHDSIK
B4T [VP1 (136–154)]4-3A (21–35)
Ac-PVTNVRGDLQVLAQKAARTC
Ac-PVTNVRGDLQVLAQKAARTC
Ac-PVTNVRGDLQVLAQKAARTC
Ac-PVTNVRGDLQVLAQKAARTC
O
O
O
O
K
K
KK–KAAIEFFEGMVHDSIK
∗All peptides in C-terminal carboxamide form. The arrow in B2T and B4T structures indicates a putative cathepsinD cleavage site [21].
dilution calculated by interpolation to give an absorbance of
1 above background.
2.6. Detection of Isotype-Specific Anti-FMDV Antibodies by
ELISA. FMDV-specific IgG1, IgG2a, IgG2b (in sera) and IgA
(in sera and nasal swabs) weremeasured using amodification
of the ELISA described above. 100 𝜇L volumes were used
throughout. In the case of nasal swabs, two consecutive
incubations with sample were performed before adding the
commercial antibody (Sigma) to mouse IgA, in order to
increase the sensitivity of the assay. Isotyping ELISA was per-
formed using a goat anti-mouse specific for mouse isotypes
and as secondary a rabbit anti-goatHRP-IgG (both by Sigma).
Plates were developed by TMB before the stop solution
(0.16M H
2
SO
4
) was added and read at 450 nm as above.
Endpoint titers were expressed as the reciprocal log
10
of
serumdilutions giving the absorbance recorded in the control
wells (serum collected day 0) plus twice standard deviation.
These data were calculated by interpolation. IgA titers in
nasal swabs were expressed as the absorbance at a dilution of
1 : 10.
2.7. IFN-𝛾 Detection by ELISPOT. A mouse IFN-𝛾 ELISPOT
reagent kit was used according tomanufacturer’s instructions
(BD Biosciences). Briefly, after red blood cell lysis, (1 and
8 × 105) splenocytes were distributed in triplicate wells of
Immobilon-P hydrophobic PVDF 96-well plates (Millipore)
previously coated with an anti-mouse IFN-𝛾 antibody, and
then blocked with RPMI 1640 (Gibco) supplemented with
glutamine, penicillin/streptomycin, and 10% inactivated FSB.
Cells were stimulated with either autologous peptide at a
concentration of 0.4𝜇g/well or with 1𝜇g/well of sucrose
gradient-purified FMDV (O UKG 11/2001). Triplicate wells
with 8 × 105 cells without peptide were used to estimate
nonspecific activation. As positive control, triplicate wells
with 8 × 105 cells were stimulated with phytohemagglutinin
(Sigma) at 10𝜇g/mL per well. After 48 h at 37∘C, 5% CO
2
and
95% relative humidity, plateswerewashed and incubatedwith
a biotinylated anti-mouse IFN-𝛾 antibody followed by HRP-
streptavidin. Antibody binding was visualized by the sub-
strate 3-amino-9-ethylcarbazole. The frequency of peptide-
and virus-specific T cells present in the responding popula-
tion was expressed as the mean number of spot-forming cells
(SFC) counted in stimulated wells per 106 splenocytes.
2.8. Statistical Analyses. Statistical significance between three
and more groups was calculated with one-way ANOVA,
followed up by multiple comparison post-tests (Bonferroni
or Tukey test depending on the sample sizes compared). Sta-
tistical tests were performed using Prims software (GraphPad
Software). 𝑃 values are depicted as follows: ∗𝑃 < 0.05; ∗∗𝑃 <
0.01; and ∗∗∗𝑃 < 0.001.
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Figure 1: Time course study of antibody responses to FMDV in sera
analyzed by ELISA. Specific antibody titers against FMDV (O UKG
11/2001) measured by ELISA in serum samples collected at days 0,
14, 20, and 39 postimmunization. Antibody titers were expressed as
the reciprocal log
10
of the last dilution calculated by interpolation to
give an absorbance of 1 above background. Each point corresponds
to the geometric mean of a least two determinations. In all cases the
standard deviation was <1.0. Arrows indicate immunization (first
dose and boost) dates.
3. Results
3.1. B and T Epitope Relative Positioning and B Epitope Multi-
plicity Are Both Essential for Anamnestic Humoral Responses
against FMDV. Various presentations of the FMDV B and
T epitopes (Table 1) were used to address issues such as (i)
the effect of a T epitope on immunogenicity or the ideal
relative orientation of juxtaposed B and T epitopes displayed
in linear peptides and (ii) how B epitope multiplicity bore on
the immune response of branched constructs B
2
T and B
4
T.
In contrast to B cell epitopes, for which multiple presentation
has a favourable effect on the immune response (see below),
T-cell stimulation and the ensuing enhancement in immune
response are achievable by a single copy of the epitope.
Upon this rationale, T
2
B and T
4
B architectures, though
synthetically feasible, were predicted as unpromising hence
disregarded for this study.
Specific anti-FMDV antibodies were determined by
ELISA in the sera of peptide-immunized mice collected at
days 0, 14, 20, and 39. As expected, no anti-FMDV antibodies
were detected in animals inoculated with peptide T (data not
shown). On the contrary, all peptides in Table 1 containing
the B cell epitope elicited significant (> 1log
10
) anti-FMDV
titers after a single dose (Figure 1). However, clear differences
among the peptides were recorded in the humoral response
induced by the booster injection. Thus, only the branched
B
4
T and B
2
T constructs and monomeric BT, with the B at
the N-terminus and followed by the T-cell epitope sequence,
BT TB B
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Figure 2: Antibody responses to FMDV in sera analyzed by
neutralization assay at day 39 postimmunization. The VNT titers
determined in each group of mice were expressed as the reciprocal
(log
10
) of the last dilution able to neutralize 100 TICD
50
of homolo-
gous virus. Animals with VNT ≥ 1 are considered seropositive. Each
symbol represents the value for an individual animal. Horizontal
lines indicate the mean value for each group of animals. Statistical
differences between B
2
T group and the others are indicated by 𝑃
values.
were able to induce secondary antibody responses after re-
exposure to immunogen.This suggests that placing the B-cell
epitope at the N-terminal to the T-cell epitope is essential for
effective cooperation, particularly for specific B-cell memory
induction.
Regarding the magnitude of humoral response, the titre
of specific antibodies against FMDV was highest in mice
immunized with dendrimeric B
2
T (average titer 4.2±0.6 SD),
well above (about 1 log) those of tetravalent B
4
T and linear
BT, both of which induced similar responses.
3.2. Multiple Presentation of B-Cell Epitopes in Dendrimeric
Constructions Significantly Enhances the Generation of Specific
Virus Neutralizing Antibodies. Clear and significant differ-
ences in the virus neutralizing antibody titers (VNT) were
found after immunization with either dendrimeric or linear
peptides. The highest VNT was detected in mice immunised
with bivalent B
2
T (Figure 2). All the animals within this
group (𝑛 = 9) had significant VNT (> 1 log). The magnitude
of neutralizing antibody response in B
2
T group was even
significantly higher than that induced by the other den-
drimeric peptide assayed, the B
4
T construction (𝑃 < 0.001).
These statistical differences in the neutralizing antibody titers
induced by the peptide B
2
T were also found relative to the
monomeric constructions (BT, TB, and B) (Figure 2).
Regarding VNT induced by the monomeric peptides
(BT, TB, and B), they were only detectable in the first (BT-
immunized) group, albeit below the significance threshold,
(3 out of 6 immunized mice). These results suggest that
multimeric presentation of B-cell epitopes in the dendrimers,
as well as the presence of a T-cell epitope in an adequate
orientation in linear peptides, enhance the induction of VN
antibodies. Again, no anti-FMDV neutralizing antibodies
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Figure 3: Isotype-specific antibody (IgG1 and IgG2a/G2b) responses to FMDV in sera analyzed by ELISA at day 39 postimmunization.
Endpoint titers were expressed as the reciprocal log
10
of serum dilutions giving the absorbance recorded in the control wells (serum collected
day 0) plus twice standard deviation. Each symbol represents the value of individual mouse. Horizontal lines indicate the mean value for each
group of animals.
were detected in animals inoculated with peptide T (data not
shown).
3.3. Incorporation of the T-Cell Epitope Is Required to Elicit
IgG2 Responses. We next investigated the ability of the
different peptides delivered subcutaneously to induce specific
isotype IgG1 and IgG2a/IgG2b antibodies. As shown in Figure
3, B
2
T was the construction that induced significantly higher
levels of the anti-FMDV antibodies of the three isotypes. In
addition, isotyping of the anti-FMDV antibodies revealed a
Th1/Th2 balanced profile when the peptides harbour the T-
cell epitope in a suitable orientation. Thus, animals immu-
nized with peptides TB and B did not show specific IgG2b
titers and only one of the mice immunized with peptide B
elicited IgG2a titers.These results suggest that class-switching
(production of IgG2a and IgG2b) of the FMDV antibodies
induced by linear peptides requires the cooperation of CD4+
lymphocytes. On the other hand, multimerization of the B-
cell epitope in the T-cell epitope-containing divalent den-
drimers results in improved titers of the three IgG isotypes.
3.4. Multiple Presentation of the B-Cell Epitope Enhances
Systemic and Local Specific IgA Responses. To investigate the
capacity of the peptides assessed to elicit systemic and local
specific IgA responses, serum samples and nasal fluids were
analysed by an IgA-specific ELISA (Figure 4).The higher IgA
responses, in most of the immunized mice, were elicited by
multimeric peptides (B
4
T and B
2
T). Statistical differences
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Figure 4: Systemic (serum) and local (nasal) IgA antibody responses to FMDV determined by ELISA at day 39 postimmunization. (a) IgA
antibody titers against FMDV. Endpoint titers were expressed as described in Figure 3. Each symbol represents the value for an individual
mouse. Horizontal lines indicate the mean value for each group of animals. (b) IgA antibody titers against FMDV determined in nasal fluids.
Titers are expressed as the OD at 450 nm value obtained using a 1 : 10 dilution.
were found between FMDV-specific IgA antibodies titers
elicited by peptides B
2
T and B
4
T and the three monomeric
peptides, but not between both dendrimeric constructions
(Figure 4).Thus, multimerization of the B-cell epitope results
in an improvement of both sera and nasal specific IgA titers.
3.5.Multiple Presentation of the B-Cell Epitope Improves T-Cell
Mediated IFN-𝛾 Release. Freshly collected splenocytes were
stimulated in vitro with either the immunizing peptide or
FMDV. After 48 h incubation, cells were harvested and their
activation was analyzed by an IFN-𝛾 ELISPOT assay. All the
synthetic peptides including that corresponding to the T-cell
epitope were able to induce significant release of this cytokine
after in vitro recall with the corresponding antigens, peptide
and virus (Figure 5).The highest release of IFN-𝛾 in response
to in vitro recall with FMDV was induced by B
4
T, followed
by B
2
T construction. However, when the corresponding
peptides were used as in vitro stimuli, IFN-𝛾 release was
higher induced by B
2
T peptide. Differences with monomeric
peptides were statistically significant between B
2
T and/or
B
4
T versus BT, TB, and B, after stimulation with peptide
and virus, respectively. Only 3 out of 6 animals immunized
with linear peptides were responders in the ELISPOT assay,
while all the dendrimeric peptide-immunized mice released
detectable quantities of IFN-𝛾.
4. Discussion
The development of successful peptide vaccines has been
limited mainly by difficulties associated with in vivo stability,
poor immunogenicity of linear peptides, and by the MHC
polymorphism of the host species [23, 24]. However, recent
advances on the requirements for induction andmaintenance
of immune responses, as well as on the pharmacokinetics of
peptides, have provided new strategies to enhance both pep-
tide immunogenicity and stability, and thus returned peptide-
based technologies to the forefront of vaccine design [9, 10].
The epitope density of a single antigen molecule is
convincingly regarded as a self/non-self-discriminator of
humoral responses [25, 26]. Usually, repetitive viral surface
antigens of high epitope density induce efficient direct cross-
linking of the surface Ig receptors of immature B cells,
whereas monomeric antigens of low epitope density rather
induce apparent B-cell tolerance [25, 26].This effect, together
with the facilitation of antigen internalization in antigen
presenting cells (APC) such as dendritic cells, has been
proposed as an explanation for the ability of multimeric
presentations to trigger an efficient antibody response [27].
In line with this multimerization approach, we previously
reported full protection against FMDV following vaccination
of pigs with dendrimeric peptides (B
4
T) displaying B- and
T-cell epitopes of FMDV serotype C [18]. However, the
same B and T epitopes juxtaposed colinearly elicited only
partial protection, highlighting the relevance of T-cell epitope
insertion and multimeric presentation [17].
To extend this proof of concept to epidemiologically rele-
vant FMDV serotypes, in the present study we have
designed new linear and dendrimeric peptides bearing
type O FMDV B-cell epitope sequences (from the GH
loop of VP1), and the same T-cell epitope used in previous
studies [16–18], which is highly conserved among FMDV
serotypes [28]. We have explored the contribution to
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immunogenicity of T-cell epitope incorporation in type
O FMDV linear monomeric peptides, by analyzing how
the lack of such T-cell epitope (peptide B) or the N- or
C-terminal attachment of the T to B epitope (peptides BT
an TB) affects the immune response. Our results show
that T-cell epitope incorporation in monomeric peptides is
essential for an efficient induction of antibodies, including
development of anamnestic response and anti-FMDV
neutralizing antibodies. Furthermore, data for the linear
peptides support that incorporation of the T-cell epitope in
the proper orientation relative to the B epitope (peptide BT)
is essential for the induction of effective T-cell help. Thus,
either the lack of T-cell epitope or its positioning at the N-
terminus of the B-cell epitope abrogates both the secondary
humoral response after re-exposure to immunogen (Figure 1)
and the induction of specific neutralizing antibodies (Figure
2). Class-switching (production of IgG1, IgG2a, and IgG2b) is
a process that requires the contribution ofCD4+ lymphocytes
[4]. ImmunizationwithTBorBpeptides did not elicit specific
IgG2 antibodies (Figure 3). Therefore, adequate orientation
of the T-cell epitope in the monomeric peptides results in
both enhanced humoral response and in a bias towards Th-1
type immunity. In this regard, it is worth recalling that in both
linear constructions the B and T epitopes are juxtaposed,
not separated by any connecting unit. These two different
epitope arrangements define in fact rather different structural
patterns, in spite of identical amino acid composition. One
should therefore not exclude that such different molecular
positioning underlies the different processing of BT and TB
peptides, altering the T-cell epitope binding to MHC or the
recognition of the B-cell epitopes by B cells.
From these results we can conclude that, in CD1 mice,
the immune response to this particular B-cell epitope in the
GH loop of VP1 is T-cell-dependent, requiring an efficient
cooperation of specific CD4+ lymphocytes. This result is
consistent with studies in cattle by Juleff et al. [29], who
found that CD4 depletion substantially inhibited antibody
responses to GH loop peptide VP1(135–156), indicating
that responses to this particular site in cattle were T-cell-
dependent. Interestingly, while N-terminal positioning of
the T-cell epitope (TB peptide) failed to elicit anti-FMDV
antibodies, cellular responses were evoked in immunized
mice (Figure 5). This suggests that T-cell epitope orientation
is only relevant for efficient B-T cooperation, but does not
significantly affect in vivo priming of peptide-specific T-cells
upon in vitro recall to release IFN𝛾 in response to such
stimulation (Figure 5). In this regard, some questions still
remain to be addressed. For example, it would be interesting
to determine more precisely how effector and memory T
cells are activated after immunization with the dendrimeric
peptide, andwhich cell subset (T, NKT,NK, B, or professional
APCs) is responsible for IFN𝛾 production. These analyses
would likely provide some explanation for the differences
between tetra- and bivalent constructions in their IFN𝛾
response to virus or peptide. This study has also confirmed
our previous findings with type C FMDV dendrimeric con-
structions. ResultswithB
4
TandB
2
Tdendrimers support that
multiple presentation of the B-cell epitope is advantageous
over simple juxtaposition for induction of humoral and
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Figure 5: Frequency of peptide- and virus-specific IFN𝛾-producing
cells in the spleen of immunized mice. IFN𝛾-producing cells were
measured by ELISPOT assay in four animals from each group. Cells
were stimulated with peptide (white bars) or FMDV (grey bars).
Data are presented as the mean for four mice; error bars represent
standard deviation.
cellular immune responses [17, 18]. Furthermore, we have
shown that B
2
T, a downsized version of B
4
T with only two
copies of the B-cell epitope, elicits similar or even better
responses [20]. We still do not have an explanation for this
somewhat unexpected observation, although one could con-
jecture that differences in epitope multiplicity/display might
reduce B-cell receptor cross-linking efficiency and eventually
lower B
4
T immunogenicity relative to B
2
T.
Dendrimeric and linear peptides also performed differ-
ently with regard to IgA antibody titers. As most pathogens,
FMDV included, enter the body through mucosal surfaces
[30], mucosal IgA responses are an effective, front-line way
of fighting infection. There is early evidence of the role of
specific IgA in protection against FMDV [31], pointing out
that effective stimulation of mucosal IgA response would be
crucial for the successful development of FMDV vaccines
[17, 32, 33]. Consistently with our previous results [18, 20],
FMDV type O bi- and tetravalent constructions induced
high mucosal responses by parenteral administration (Figure
4(b)), while none of the monomeric peptides were able
to induce nasal FMDV IgA titers. The natural pathway of
mucosal immune induction involves direct delivery of the
immunogen to a mucosal surface and local processing of the
antigen in specialized aggregates of lymphoid tissue, termed
mucosal inductive sites [34, 35]. Stimulated lymphocytes
then migrate to the corresponding mucosal surface where
antigen-specific IgA and IgG are locally produced, and
specific T cells reside to protect that mucosal surface from
pathogen attack [35]. In contrast to this natural induction
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pathway, B
4
T and B
2
T dendrimers can induce high mucosal
immune responses by parenteral administration. Alternative,
nonmutually exclusive mechanisms can be invoked for the
production of secretory antibodies after parenteral adminis-
tration of the antigen, including (i) direct diffusion of soluble
or phagocytosed antigens to mucosa-associated lymphoid
tissue and/or (ii) activation of antigen-presenting cells at
draining lymph nodes, which then migrate to mucosa-
associated lymphoid tissue [35, 36].Thedendrimeric peptides
are more stimulatory for the mucosal immune system than
monomeric peptides probably due to better targeting to den-
dritic cells. Taken together, these results confirmdendrimeric
peptides as good candidates for future mucosal vaccines, able
to overcome some of the main problems associated with
mucosal administration (local degradation, physical ejection
of the vaccine, etc.) [34].
In addition to confirming that multimerization is an
important strategy in the triggering of a humoral response,
herein we have shown it can also improve IFN-𝛾 release
by primed splenocytes after in vitro recall. Thus, higher
IFN-𝛾 release levels were observed after immunization with
dendrimeric (particularly B
4
T) than with linear peptides.
IFN𝛾, a key cytokine produced primarily by NK and T cells,
facilitates host defense against intracellular pathogens [23].
CD4+ T cell activation by DCs triggers their differentiation
along two distinct and mutually exclusive pathways: (i) Th1-
type CD4+ T cells essentially produce IFN-𝛾 and TNF-𝛼,
which assist in the elimination of intracellular pathogens both
directly (cytokine responses) and indirectly via their support
tomacrophage activation andCD8+T cell differentiation and
(ii)Th2-type CD4+ T cells essentially produce IL-4, IL-5, and
IL-13 which are directly involved in the defense against extra-
cellular pathogens such as helminths [26]. Enhanced uptake
by DCs of high epitope density antigens, such as dendrimeric
peptides and/or their mechanism of internalization [27, 37],
might explain upregulated IFN-𝛾 production. In contrast,
processing of linear peptides by other APCs (macrophages,
neutrophils, and B cells), not so efficient in activation of Th1
responses, could explain the lower IFN-𝛾 release levels in
mice immunized with these peptides.
Finally, the fact that a bivalent peptide is more immuno-
genic than its tetravalent congener has also important
implications for developing cost-effective FMDV peptide
vaccines. Production of B
4
T required exhaustive purification
and even so yielded a not-quite-homogeneous end product
[18], whereas the simpler design and improved conjugation
chemistry of the B
2
T constructs translated into significantly
improved yields, purity, and hence much lower production
costs [20]. At the time of this writing, it seems clear that the
B
2
T construct shows undeniable advantages as a candidate
for a peptide-based FMDV vaccine.
5. Conclusions
The above results highlight the relevance of adequately
selecting specific B- and T-cell epitopes to be included in a
peptide vaccine, as well as the importance of B/T cell epitope
relative positioning for successful eliciting of an immune
response. In our FMDV model, B-cell epitope multivalency
by means of dendrimeric constructions is shown to improve
immunogenicity, including induction of mucosal IgA, rela-
tive to mere linear juxtaposition of B- and T-cell epitopes.
Moreover, bivalent dendrimeric constructions elicit similar
or even better immune responses than tetravalent ones.
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